Tandem Diabetes Care (TNDM) reported $1.0B in revenue for fiscal 2025, +7.9% year on year. That ranks #1759 by revenue among 2853 SEC filers and #161 in Healthcare. It posted a net loss of −$205M for the same year. Revenue has grown 31.9% a year on average since 2016 ($84.2M then). The fiscal 2025 balance sheet shows $881M in total assets, $90.6M in cash and $310M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.0B | +7.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $546M | +11.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$187M | −$88.1M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$205M | −$109M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$9.7M | −$33.9M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $19.9M | +3.7% | FY20252025-12-31 |
| Total assetsAssets | $881M | −8.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $155M | −41.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $90.6M | +30.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $310M | +0.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $247M | −$20.4M | Open → |
| Q2 20262026-06-30 | $255M | −$21.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 148 of 161 companies compared | −20.2% | |
| Operating marginRank 149 of 160 companies compared | −18.5% | |
| R&D as share of revenueRank 27 of 102 companies compared | 19.0% | |
| Cash as share of revenueRank 95 of 160 companies compared | 8.9% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Tandem Diabetes Care Inc
- Ticker
- TNDM
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001438133
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| EmbectaEMBC | $1.1B | $95.4M |
| Acadia PharmaceuticalsACAD | $1.1B | $391M |
| Legend BiotechLEGN | $1.0B | −$297M |
| Tandem Diabetes CareTNDM | $1.0B | −$205M |
| Guardant HealthGH | $982M | −$416M |
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
| Pennant GroupPNTG | $948M | $29.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Tandem Diabetes Care — Key figures |url=https://companiesranked.com/en/company/tandem-diabetes-care |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Tandem Diabetes Care — Key figures. CompaniesRanked. https://companiesranked.com/en/company/tandem-diabetes-careBibTeX
@misc{companiesranked-en-company-tandem-diabetes-care-2026,
author = {{CompaniesRanked}},
title = {{Tandem Diabetes Care — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/tandem-diabetes-care}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001438133-26-000010 · February 19, 2026
{{cite web |title=Tandem Diabetes Care — Key figures — 10-K (0001438133-26-000010) |url=https://www.sec.gov/Archives/edgar/data/1438133/000143813326000010/tndm-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.